|
1
|
Houslay MD: Adaptation in cyclic AMP
signalling processes: a central role for cyclic AMP
phosphodiesterases. Semin Cell Dev Biol. 9:161–167. 1998.
|
|
2
|
Zhang L, Murray F, Zahno A, et al: Cyclic
nucleotide phosphodiesterase profiling reveals increased expression
of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl
Acad Sci USA. 105:19532–19537. 2008.
|
|
3
|
Marko D, Romanakis K, Zankl H,
Furstenberger G, Steinbauer B and Eisenbrand G: Induction of
apoptosis by an inhibitor of cAMP-specific PDE in malignant murine
carcinoma cells overexpressing PDE activity in comparison to their
nonmalignant counterparts. Cell Biochem Biophys. 28:75–101.
1998.
|
|
4
|
Rahrmann EP, Collier LS, Knutson TP, et
al: Identification of PDE4D as a proliferation promoting factor in
prostate cancer using a Sleeping Beauty transposon-based somatic
mutagenesis screen. Cancer Res. 69:4388–4397. 2009.
|
|
5
|
Pullamsetti SS, Banat GA, Schmall A, et
al: Phosphodiesterase-4 promotes proliferation and angiogenesis of
lung cancer by crosstalk with HIF. Oncogene. 32:1121–1134.
2012.
|
|
6
|
Kolosionek E, Savai R, Ghofrani HA, et al:
Expression and activity of phosphodiesterase isoforms during
epithelial mesenchymal transition: the role of phosphodiesterase 4.
Mol Biol Cell. 20:4751–4765. 2009.
|
|
7
|
Lin DC, Xu L, Ding LW, et al: Genomic and
functional characterizations of phosphodiesterase subtype 4D in
human cancers. Proc Natl Acad Sci USA. 9:6109–6114. 2013.
|
|
8
|
Lo KW, Chung GT and To KF: Deciphering the
molecular genetic basis of NPC through molecular, cytogenetic, and
epigenetic approaches. Semin Cancer Biol. 22:79–86. 2012.
|
|
9
|
Spano JP, Busson P, Atlan D, Bourhis J,
Pignon JP, Esteban C and Armand JP: Nasopharyngeal carcinomas: an
update. Eur J Cancer. 39:2121–2135. 2003.
|
|
10
|
Lee AW, Poon YF, Foo W, et al:
Retrospective analysis of 5037 patients with nasopharyngeal
carcinoma treated during 1976–1985: overall survival and patterns
of failure. Int J Radiat Oncol Biol Phys. 23:261–270. 1992.
|
|
11
|
Chua DT, Nicholls JM, Sham JS and Au GK:
Prognostic value of epidermal growth factor receptor expression in
patients with advanced stage nasopharyngeal carcinoma treated with
induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol
Phys. 59:11–20. 2004.
|
|
12
|
Leong JL, Loh KS, Putti TC, Goh BC and Tan
LK: Epidermal growth factor receptor in undifferentiated carcinoma
of the nasopharynx. Laryngoscope. 114:153–157. 2004.
|
|
13
|
Ruan L, Li XH, Wan XX, et al: Analysis of
EGFR signaling pathway in nasopharyngeal carcinoma cells by
quantitative phosphoproteomics. Proteome Sci. 9:352011.
|
|
14
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000.
|
|
15
|
Blagoev B, Ong SE, Kratchmarova I and Mann
M: Temporal analysis of phosphotyrosine-dependent signaling
networks by quantitative proteomics. Nat Biotechnol. 22:1339–1345.
2004.
|
|
16
|
Berg M and Soreide K: EGFR and downstream
genetic alterations in KRAS/BRAF and PI3K/AKT pathways in
colorectal cancer: implications for targeted therapy. Discov Med.
14:207–214. 2012.
|
|
17
|
Chinese Committee for Staging of
Nasopharyngeal Carcinoma. Report on revision of the Chinese 1992
staging system for nasopharyngeal carcinoma. J Radiat Oncol.
2:233–240. 2013.
|
|
18
|
Xu T, Xiao D and Zhang X: ECRG4 inhibits
growth and invasiveness of squamous cell carcinoma of the head and
neck in vitro and in vivo. Oncol Lett. 5:1921–1926.
2013.
|
|
19
|
Xu T, Yu CY, Sun JJ, et al: Bone
morphogenetic protein-4-induced epithelial-mesenchymal transition
and invasiveness through Smad1-mediated signal pathway in squamous
cell carcinoma of the head and neck. Arch Med Res. 42:128–137.
2011.
|
|
20
|
National Research Council. Guide for the
Care and Use of Laboratory Animals. 8th edition. The National
Academies Press; Washington, DC: 2011
|
|
21
|
Efferson CL, Winkelmann CT, Ware C, et al:
Downregulation of Notch pathway by a gamma-secretase inhibitor
attenuates AKT/mammalian target of rapamycin signaling and glucose
uptake in an ERBB2 transgenic breast cancer model. Cancer Res.
70:2476–2484. 2010.
|
|
22
|
Yip WK, Leong VC, Abdullah MA, Yusoff S
and Seow HF: Overexpression of phospho-Akt correlates with
phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal
carcinoma. Oncol Rep. 19:319–328. 2008.
|
|
23
|
Baselga J: The EGFR as a target for
anticancer therapy - focus on cetuximab. Eur J Cancer. 37(Suppl 4):
S16–S22. 2001.
|
|
24
|
Sung FL, Pang RT, Ma BB, Lee MM, Chow SM,
Poon TC and Chan AT: Pharmacoproteomics study of cetuximab in
nasopharyngeal carcinoma. J Proteome Res. 5:3260–3267. 2006.
|
|
25
|
Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK,
Yang D and Zeng YX: EGFR tyrosine kinase inhibitor AG1478 inhibits
cell proliferation and arrests cell cycle in nasopharyngeal
carcinoma cells. Cancer Lett. 169:27–32. 2001.
|
|
26
|
Huang WC, Hsu RM, Chi LM, Leu YL, Chang YS
and Yu JS: Selective downregulation of EGF receptor and downstream
MAPK pathway in human cancer cell lines by active components
partially purified from the seeds of Livistona chinensis R.
Brown. Cancer Lett. 248:137–146. 2007.
|
